# Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers

> **NCT04614233** · PHASE4 · TERMINATED · sponsor: **Yale University** · enrollment: 64 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DIETARY_SUPPLEMENT:** RiduZone (90% OEA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04614233
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-06
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-10-04
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** PI changed institutions
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614233, "Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04614233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*